Pharmacological Considerations of Neuroleptic Malignant Syndrome in a Patient on a Long-Acting Antipsychotic
Journal of the Academy of Consultation-Liaison Psychiatry · 2023
DOI: 10.1016/j.jaclp.2023.01.010 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the Academy of Consultation-Liaison Psychiatry, 2023. Verfasst von Amanpreet Mashiana und 1 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Roseville Medical Center, ED Admin, Roseville, CA; University of California Davis Health, Sacramento, CA. Electronic address: Amanpreet.K.Mash…. Hauptthemen laut MEDLINE: Antipsychotic Agents, Neuroleptic Malignant Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Kaiser Roseville Medical Center, ED Admin, Roseville, CA; University of California Davis Health, Sacramento, CA. Electronic address: Amanpreet.K.Mashiana@kp.org.
- University of California Davis Health, Sacramento, CA.
Zitieren
APA
Mashiana, A., & Pierce, M. (2023). Pharmacological Considerations of Neuroleptic Malignant Syndrome in a Patient on a Long-Acting Antipsychotic. Journal of the Academy of Consultation-Liaison Psychiatry. https://doi.org/10.1016/j.jaclp.2023.01.010
Vancouver
Mashiana A, Pierce M. Pharmacological Considerations of Neuroleptic Malignant Syndrome in a Patient on a Long-Acting Antipsychotic. Journal of the Academy of Consultation-Liaison Psychiatry. 2023. doi:10.1016/j.jaclp.2023.01.010
BibTeX
@article{Mashiana2023,
author = {Mashiana, Amanpreet and Pierce, Mackenzie},
title = {Pharmacological Considerations of Neuroleptic Malignant Syndrome in a Patient on a Long-Acting Antipsychotic},
journal = {Journal of the Academy of Consultation-Liaison Psychiatry},
year = {2023},
doi = {10.1016/j.jaclp.2023.01.010}
}
EUVIMED